Erschienen in:
07.07.2022 | Liver (E Tapper, Section Editor)
The Role of Statins in Cirrhosis
verfasst von:
Carlos Moctezuma-Velazquez, MD, MSc, Juan Gonzalez Abraldes, MD, PhD
Erschienen in:
Current Treatment Options in Gastroenterology
|
Ausgabe 3/2022
Einloggen, um Zugang zu erhalten
Abstract
Purpose of review
To critically analyze current evidence regarding the role of statins in cirrhosis with particular emphasis on the source of the evidence.
Recent findings.
Most evidence is from observational studies; the few data of clinical trials does not support using statins to prevent rebleeding, but suggests that properly designed trials should be conducted to assess a potential disease-modifying effect. Current evidence is not enough to support their use in prevention of decompensation, acute-on-chronic liver failure, hepatocellular carcinoma, infection, or mortality. Regarding safety, outside of clinical trials, statins are not contraindicated in patients with compensated cirrhosis. In patients with early decompensated cirrhosis, they should be used with caution or deprescribed. In Child–Pugh C patients, statins are contraindicated.
Summary
Current evidence is not enough to support the use of statins in patients with cirrhosis for any other indication than treatment of dyslipidemia and/or to reduce cardiovascular risk. However, current ongoing trials will answer if their role can be expanded to improve cirrhosis outcomes.